On May 14, 2025, RBC Capital analyst Brian Abrahams reiterated his rating on Applied Therapeutics (APLT, Financial), maintaining a "Sector Perform" designation. This reflects a consistent outlook on the stock's performance within its industry, as indicated by the unchanged rating.
In conjunction with the rating reiteration, RBC Capital also maintained its price target for Applied Therapeutics (APLT, Financial) at USD 1.50. This price target remains steady from the previous mark, indicating no expected change in the stock's valuation according to RBC Capital's latest assessment.
The rating and price target suggest stability in the analyst's expectations for Applied Therapeutics (APLT, Financial), providing a clear perspective to stakeholders who are closely monitoring the company's market performance. Investors might find reassurance in the unchanged assessment, signaling consistent confidence in the firm's strategic direction and its place within the sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Applied Therapeutics Inc (APLT, Financial) is $2.88 with a high estimate of $5.00 and a low estimate of $1.50. The average target implies an upside of 505.65% from the current price of $0.47. More detailed estimate data can be found on the Applied Therapeutics Inc (APLT) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Applied Therapeutics Inc's (APLT, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
